<table>
<thead>
<tr>
<th>Title</th>
<th>Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Ma, BBY; Lui, VWY; Poon, FF; Wong, SCC; To, KF; Wong, E; Chen, H; Lo, KW; Tao, Q; Chan, ATC</td>
</tr>
<tr>
<td>Citation</td>
<td>Investigational New Drugs, 2010, v. 28 n. 3, p. 326-333</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2010</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/124032">http://hdl.handle.net/10722/124032</a></td>
</tr>
<tr>
<td>Rights</td>
<td>Springer Science+Business Media, LLC; This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

Brigette B.Y. Ma · Vivian W.Y. Lui · Fan Fong Poon · S.C. Cesar Wong · Ka Fai To · Elaine Wong · Honglin Chen · Kwok Wai Lo · Qian Tao · Anthony T.C. Chan

Received: 10 August 2009 / Accepted: 28 August 2009 / Published online: 16 September 2009 © Springer Science + Business Media, LLC 2009

Summary This study evaluated the preclinical activity and molecular predictors of response to gefitinib (Iressa®, Astra Zeneca Inc, UK) in nasopharyngeal carcinoma (NPC). The activity of gefitinib was evaluated in four human NPC cell lines—HK1, HONE-1, CNE2, C666-1. A representative gefitinib-sensitive (HK1, IC$_{50}$=250 nM) and gefitinib-resistant cell line (HONE-1, IC$_{50}$>15 μM) were selected and compared for expression of epidermal growth factor receptor (EGFR) and related ligands, and activation of downstream proteins. Gefitinib induced G1 cycle arrest, apoptosis and inhibited cell invasion more significantly in HK1 than HONE-1 cells. HK1 expressed higher levels of p-EGFR, lower p-AKT and phospho-signal transducer and activator of transcription 3 (p-STAT3) than other cell lines. EGFR gene was found to be amplified in HK1. Gefitinib at IC$_{50}$ concentrations significantly suppressed EGF-induced activation of p-EGFR, phospho-mitogen-activated protein kinase (p-MAPK) and p-STAT3, but p-AKT showed persistent activation in HK1 and HONE-1 cells. There was no difference in EGFR-ligand expression between the 4 NPC cell lines. In NPC samples derived from non-responders to gefitinib, 50% and 60% showed cytoplasmic and nuclear pi-EGFR expression, respectively, and 33% showed p-AKT expression. EGFR or KRAS mutations were not detected. This study suggests that most NPC cell lines are intrinsically resistant to gefitinib (except HK1 cells), and further studies are needed to confirm whether EGFR gene amplification and persistent AKT activation may influence response to gefitinib in NPC.

Keywords Head and neck cancer · Gefitinib · Epidermal growth factor receptor

Introduction

Nasopharyngeal carcinoma (NPC) is endemic to China and the Southeast Asian region and areas like Hong Kong, where it reaches a peak incidence rate of around 20 per 100,000 person-years [1]. Our previous work supports...
epidermal growth factor receptor (EGFR) as a potential therapeutic target for NPC, as it is overexpressed in 80% of NPC and represents a negative prognostic factor [2]. Based on our work which has demonstrated the preclinical and clinical activity of the anti-EGFR antibody, cetuximab in NPC [3, 4] in NPC, we evaluated the EGFR tyrosine kinase inhibitor, gefitinib (ZD1839, Iressa®, Astra Zeneca Inc, Macclesfield, UK) in a previously reported phase II trial in advanced NPC [5]. The objectives of the current study were to determine the preclinical activity and molecular predictors of response to gefitinib in NPC cell lines and in primary tumor biopsies obtained from our phase II study. These factors included the activation level of EGFR and its downstream signaling mediators (mitogen-activated protein kinase, MAPK; protein kinase B, AKT; signal transducer and activator of transcription 3, STAT3); expression level of EGFR-related ligands (epidermal growth factor, EGF; amphiregulin; heparin-binding EGF-like growth factor, HB-EGF; transforming growth factor alpha, TGF-α); and the presence of any EGFR or KRAS mutations.

Method and materials

Cell culture

Analyses were carried in four human-derived NPC cell lines (CNE-2, C666-1, HONE-1 and HK1) and the normal nasopharyngeal epithelial cell line NP69 was used as a control.

Reagents and antibodies

Gefitinib was kindly provided by Astra Zeneca Inc (Macclesfield, UK). For in vitro experiments, the following antibodies were purchased from Cell Signaling Technology (Beverly, USA): anti-total EGFR, anti-phospho(p)-EGFR (Y1068), anti-total STAT3, anti-p-STAT3 (Tyr705); anti-total p44/42MAPK (Thr202/Tyr204), anti-p-p44/42MAPK (Thr202/Tyr204), AKT (#9272S), anti-total AKT and p-AKT (Ser473) (#9270S), antibody against cleaved poly(ADP-ribose) polymerase (PARP) proteins. Anti-beta-actin antibody was from Calbiochem, Merck (Gibbstown, USA). The following antibodies from Cell Signaling Technology (Beverly, USA) were used for immunohistochemistry: p-AKT (Ser473), anti-p-EGFR (Tyr 845), and p-EGFR (Tyr 992). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was purchased from PeproTech (London, UK).

Cell viability assay

Cells were treated with increasing concentrations of gefitinib (from 0 to 100 μM) for up to 48 hours (h) and cytotoxicity was assessed by the MTT assay. Cells were cultured in 48-well plates (2,500–7,000 cells/well) and then incubated with gefitinib at 24 h for 48 to 72 h. DMSO was used as a blanking control. The drug concentration at which 50% of maximum growth inhibition was achieved was determined as the IC50 using the GraphPad PRISM software (ISS, San Diego, CA). All experiments were repeated in triplicates.

Western blot and apoptosis

Western Blot was used to detect the expression of total and phosphorylated levels of EGFR, MAPK, STAT3 and AKT in NPC cell lines, at basal condition and after treatment with gefitinib at or near IC50 concentration for 48 h under serum-starved and EGF-stimulated (20 ng/ml) conditions. Apoptosis was determined via detection of PARP cleavage proteins. Cell lysates were prepared as previously described [6] and 25 μg of total protein was subjected to SDS-PAGE and immunoblotting with specific antibodies as listed above. Supersignal West Pico Chemiluminescence Western blotting detection reagents (ThermoFisher Scientific, USA) were used for signal detection by autoradiography.

RNA extraction and RT-PCR

The expression levels of EGFR-related ligands were determined by Reverse Transcription-Polymerase Chain Reaction (RT)-PCR. Total RNA was extracted from cell pellets using TriReagent (Molecular Research Center, USA) and treated with DNase by a TURBO DNA-free™ Kit (Ambion, USA). One μg of RNA was used for reverse transcription using the Go-Taq polymerase (Promega Co, USA) using GAPDH as control as previously described [7]. The primers and conditions are outlined in Table A of the section on Supplementary Material. RT-PCR products were analyzed on a 1.8% agarose gel.

Cell cycle

Cells were plated in 100-mm² Petri dishes (3 to 4 × 10⁵) and then treated with gefitinib for up to 24 h. Cells were collected by trypsinization, fixed with 70% cold ethanol and stored at −20°C. DNA staining was performed with a solution containing RNase (0.2 mg/ml) and propidium iodide (0.05 μg/ml). Analysis was performed using a FACSscan flow cytometer and data were processed with CELLQuest software (Becton Dickinson Co, USA).

Matrigel invasion assay

The cell invasion assay was performed using a Matrigel Invasion Chamber with a pore size of 8 μm (Becton Dickinson Co, USA). Cells were seeded at a density of
of 15) of a phase II trial of gefitinib in NPC [5]. This clinical protocol was approved by the Institutional Ethics Committee and all participants gave written informed consent. Tissue sections of 4 µm thickness were immunostained using the Benchmark XT immunostainer and ultraView™ detection kit (Ventana Inc, USA). An immunostained sample of breast cancer was used as a positive control and the negative control was made by replacing the antibody with Tris buffered saline. Slides were evaluated under a light microscope at 200 times magnification by a pathologist (K.F.To). Phosphorylated-AKT (Ser473) expression was considered positive (1+) or negative, if nuclear staining was present or negative, respectively. The expression of pi-EGFR-Y845 was scored by estimating the proportion of tumor cells with positive nuclear staining (negative if none; 1+, if less than or equal to 10%; 2+, if 10–50%; 3+, if over 50%). The cytoplasmic expression of pi-EGFR-Tyr 992 was scored as previously described [2].

**Mutational analysis**

Paraffin-embedded NPC samples were deparafinized and DNA was isolated using QIAamp DNA Mini Kit (Qiagen GmbH, Germany). Sections of 130 µm thick were cut and dewaxed through suspension in 40 µL of TK buffer. To inactivate the enzyme, samples were incubated at 55°C for 3 days and heated at 95°C for 10 min. One µl of protein was used for PCR analysis, the amplicons were amplified
using AmpliTaq Gold polymerase (Applied Biosystems, USA) and purified using the High Pure PCR Purification Kit (Roche Diagnostics, USA). Sequencing was performed using the dRhodamine Terminator Cycle Sequencing Kit (Perkin-Elmer, USA) and the Applied Biosystems 310 Genetic Analyzer. The primers and PCR conditions are outlined in Table B of the section on Supplementary Material.

Results

Effect of gefitinib on growth, apoptosis, cell cycle progression and cell invasion

The IC50 value for gefitinib in HK1 cells (250 nM) was the lowest compared with the other NPC cell lines of which the IC50 values ranged between 15–40 µM, while the IC50 for NP69 was 28.6 µM (data was not shown). In order to elucidate the biological characteristics associated with sensitivity to gefitinib, HK1 and HONE-1 cell lines were chosen as a representative gefitinib-sensitive and gefitinib-resistant cell line, respectively, for all subsequent analyses described below.

When treated with gefitinib at IC50 concentrations, apoptosis was observed in both HK1 and HONE-1 cells after 24 to 48 h as evident by an increased expression of cleaved PARP (Fig. 1a and b). Exposure to gefitinib at similar concentrations also resulted in G1 cycle arrest (Fig. 1c), and inhibition of the invasive activity of HONE-1 and HK1 cells compared with control (Fig. 2).

Molecular profile of gefitinib-sensitive and gefitinib insensitive cell lines

At basal condition, the level of total and p-EGFR and p-MAPK was higher in HK1 compared to HONE-1 cells (Fig. 3a). In contrast, the level of p-AKT and p-STAT3 were higher in HONE-1 compared with HK1 cells, while there were no significant differences in the levels of total AKT, STAT3 and MAPK expression. However, such differences were not observed under EGF-stimulated conditions (Fig. 3b). When HK1 and HONE-2 cells were treated with gefitinib at or near their respective IC50 concentrations, the level of p-MAPK and p-STAT3 were significantly reduced in both cell lines (Fig. 3c). Phosphorylated AKT expression was significantly reduced when both cell lines were treated with gefitinib well above the respective IC50 concentrations (Fig. 3b). The expression level of TGF-α, EGF, HB-EGF, amphiregulin were compared in HK1 and HONE-1 cell lines. No difference was found in the ligand expression level of these cell lines (Fig. 3d). Furthermore, none of the cell lines harbored EGFR TK mutations (data not shown).

Immunohistochemistry and EGFR mutation in tumor samples

Of the pre-treatment biopsies obtained from 9 patients, only 3 samples showed mild (+1) p-AKT expression. Under half (4/9 samples) of the samples showed EGFR overexpression (cytoplasmic staining), while the 6 (out of 9) samples showed mild to moderate nuclear expression of EGFR (see Table 1 and Fig. 5). None of the tumors analyzed harbor KRAS or EGFR mutations (data not shown). Since clinical response was not observed in the previously reported phase II study [5], correlation between immunohistochemical results and clinical response was not performed.

Discussion

In this study, gefitinib was found to inhibit cell growth and invasion, induce apoptosis and G1 cycle arrest in human
NPC cell lines, as consistent with previous reports in other cancer types [9, 10]. However, the relatively high concentrations required to achieve these effects suggested that most NPC cell lines are intrinsically resistant to gefitinib, with the exception of HK1. Furthermore, treatment with gefitinib at IC₅₀ concentrations significantly inhibited EGF-induced phosphorylation of important downstream mediators of EGFR, namely, STAT3 and MAPK to a similar extent in both HK1 and HONE-1 cells, but AKT activation appeared to remain persistent in both cell lines at similar concentration. These results prompted the need to elucidate the molecular basis of these changes by evaluating the activation level of EGFR and its downstream signaling mediators, ligand expression, presence of EGFR mutations and gene amplifications in NPC, by comparing these molecular profiles between a representative gefitinib-sensitive (HK1) and a resistant cell line (HONE-1).

The 2 cell lines differed in the basal activation level of EGFR and downstream mediators, in that HK1 cells expressed a higher level of p-EGFR and p-MAPK, while HONE-1 expressed a higher level of p-AKT and p-STAT3. However, MAPK, AKT and STAT3 activation were similar in both cell lines under EGF-stimulated condition, suggesting that these signaling axes are inherently intact. Previous studies in other cancer types have associated resistance to gefitinib with increased level of MAPK (e.g. prostate cancer).
cancer cells) [11] and AKT (e.g. in lung [12] and glioma cells [13]). As consistent with our study, increased STAT3 activation can be found in gefitinib-resistant glioma cells, despite the fact that STAT3 could be easily inhibited at low doses of gefitinib [13]. As in our NPC cell lines, higher concentrations of gefitinib was required to inhibit AKT and MAPK activation compared with EGFR in gefitinib-resistant glioma cells, suggesting that the AKT signaling maybe an escape mechanism for the inhibitory effect of gefitinib [13].

EGFR was found to be amplified in the gefitinib-sensitive HK1 cell lines. Gain in gene copy number or EGFR gene amplification is a common event in NPC, and further validation is needed to elucidate whether EGFR amplifica-

---

**Table 1** Immunohistochemical analysis of NPC samples

<table>
<thead>
<tr>
<th>Patient</th>
<th>Tissue type</th>
<th>pAKT-ser473 staining</th>
<th>EGFR-Tyr 992 (cytoplasmic) staining</th>
<th>EGFR-Tyr 845 (Nuclear) staining</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NP</td>
<td>Neg</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>2</td>
<td>NP</td>
<td>Neg</td>
<td>2+</td>
<td>2+</td>
</tr>
<tr>
<td>3</td>
<td>NP</td>
<td>Neg</td>
<td>1+</td>
<td>1+</td>
</tr>
<tr>
<td>4</td>
<td>Lung metastasis</td>
<td>Neg</td>
<td>Neg</td>
<td>1+</td>
</tr>
<tr>
<td>5</td>
<td>Lung metastasis</td>
<td>1+</td>
<td>1+</td>
<td>Neg</td>
</tr>
<tr>
<td>6</td>
<td>NP</td>
<td>Neg</td>
<td>2+</td>
<td>2+</td>
</tr>
<tr>
<td>7</td>
<td>NP</td>
<td>1+</td>
<td>3+</td>
<td>Neg</td>
</tr>
<tr>
<td>8</td>
<td>Nodal metastasis</td>
<td>1+</td>
<td>3+</td>
<td>3+</td>
</tr>
</tbody>
</table>

NP primary nasopharyngeal tumor
Neg negative staining
NA not available
tion may contribute to the enhanced sensitivity towards gefitinib in NPC [14]. This is supported by studies in lung cancer samples, where increased copy number of \( \text{EGFR} \) has been associated with better response to gefitinib [15].

Increased expression of EGFR-related ligands have been shown to predict resistance to EGFR TK inhibitors in vitro, these include overexpression of TGF-\( \alpha \) in breast and pancreatic cancer cells [16, 17], and amphiregulin in breast and lung cancer cells [16, 18]. In gefitinib-resistant breast cancer cells, exposure to gefitinib led to increased nucleo-cytoplasmic trafficking of EGFR ligands, thereby suggesting the presence of an intracrine feedback loop [16]. However, the current study did not identify any differences in expression of EGFR ligands between HK1 and HONE-1 cell lines, thus excluding the possibility that reduced basal activation of STAT3 and AKT in HK1 cells might be related to altered autocrine signaling in NPC.

Our in vitro data suggests that resistance to gefitinib may be associated with lower level of EGFR activation and persistent AKT activation in NPC cell lines, therefore we examined tumor samples obtained from gefitinib-resistant participants of a previously reported phase II study [5]. The study was terminated after 15 patients were entered because no clinical response was observed, hence the small number of biopsies obtained for the current study. Around 33% (3/9 samples) of tumors weakly expressed p-AKT, which concurred with the reported 40% p-AKT overexpression rate in previous reports [19, 20]. Over 50% (5/9 samples) of the current cohort showed no cytoplasmic EGFR expression, while over 60% expressed moderate to strong nuclear EGFR expression—the latter which is a negative prognostic factor in some cancers [21]. This was unexpected as our previous report found that over 80% of NPC overexpressed cytoplasmic EGFR [2]. However, the small number of tumor samples available makes it difficult to draw conclusions. The low level of AKT activation in NPC tumors from gefitinib-resistant patients is consistent with previous studies in lung cancer, where the lack of p-AKT expression was associated with poorer clinical outcome following gefitinib [12, 22].

In summary, a high level of basal EGFR activation (possibly from \( \text{EGFR} \) gene amplification) is an important indicator for sensitivity to gefitinib, while further studies are needed to confirm whether persistent AKT activation maybe associated with resistance. Tumoral status of EGFR activation and gene amplification should be further evalu-
ated as biomarkers for selecting patients in clinical trials involving EGFR inhibitors.

Acknowledgements This study was supported by the Research Grant Council Competitive Earmarked Research Grant (Reference 444505M). Result of this study was presented in part at the Annual Meeting of the American Association of Clinical Oncology 2007, abstract 3171, April 14–18, 2007, Los Angeles, CA. We thank Astra Zeneca Inc for providing gefitinib in this study.

References